✦ LIBER ✦

P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY

✍ Scribed by Federico, A.; Cotticelli, G.; De Simini, G.; Gravina, A.G.; Miranda, A.; Sgambato, D.; Dallio, M.; De Sio, C.; Ferrante, E.; Meucci, R.; Rossetti, G.; Vitale, L.M.; Beneduce, F.; Romano, M.; Loguercio, C.

Book ID: 122107415
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 90 KB
Volume: 46
Category: Article
ISSN: 1590-8658
DOI: 10.1016/S1590-8658(14)60364-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of telaprevir (TVR)

Efficacy and safety of telaprevir (TVR) triple therapy in a ‘real-life’ cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment

✍ Werner, C. R.; Franz, C.; Egetemeyr, D. P.; Janke-Maier, P.; Malek, N. P.; Lauer 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

T-27 Efficacy and safety of telaprevir-b

T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study

✍ P. Andreone; S. Pol; S. Roberts; Z. Younossi; M. Diago; E.J. Lawitz; R. Focaccia 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Sa1041 Triple Therapy Under Real Life Co

Sa1041 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study

✍ Moog, Gero; Mauss, Stefan; Hueppe, Dietrich; Spengler, Ulrich; Schott, Eckart; E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 285 KB

Sa1050 Efficacy of Boceprevir Based Trip

Sa1050 Efficacy of Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1: The PAN Study

✍ Moog, Gero; Mauss, Stefan; Hueppe, Dietrich; Spengler, Ulrich; Schott, Eckart; E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 315 KB

T-26 Impact of anemia and ribavirin dose

T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study

✍ P. Andreone; S. Roberts; S. Pol; Z. Younossi; M. Diago; E.J. Lawitz; R. Focaccia 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB

T-28 Impact of insulin resistance on vir

T-28 Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study

✍ P. Andreone; Z. Younossi; F. Negro; L. Serfaty; S. Pol; M. Diago; S. Zeuzem; E.J 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 81 KB